Literature DB >> 1389933

Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites.

T B Kudriakova1, L A Sirota, G I Rozova, V A Gorkov.   

Abstract

1. The effect of carbamazepine (CBZ) dose change on mean plasma concentrations of CBZ, its two metabolites and apparent steady-state clearance was studied in 77 affectively ill patients receiving CBZ at doses of 100-1200 mg day-1. 2. Autoinduction of CBZ metabolism appeared to be complete within 1 week of starting CBZ therapy or dose change, and its degree was linearly related to CBZ daily dose. 3. Curvilinear plots were obtained for steady-state concentrations of CBZ and its -10,11-epoxide metabolite, and for the ratio of CBZ-10,11-epoxide to CBZ level, versus daily dose of CBZ. 4. On the contrary, steady-state concentration of CBZ-10,11-diol increased proportionately with the dose. This indicates that there is no dose dependency in absorption of CBZ, and that dose-dependent autoinduction of CBZ metabolism is the main cause of the curvilinear relationship between dose and steady-state concentration of CBZ and its intermediary metabolite, CBZ-10,11-epoxide.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1389933      PMCID: PMC1381352          DOI: 10.1111/j.1365-2125.1992.tb04089.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Relationship of intraindividual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism.

Authors:  T Tomson; J O Svensson; P Hilton-Brown
Journal:  Ther Drug Monit       Date:  1989-09       Impact factor: 3.681

2.  Measuring plasma levels of carbamazepine. A pharmacokinetic study in patients with affective disorders.

Authors:  W A Nolen; G S Jansen; M Broekman
Journal:  Pharmacopsychiatry       Date:  1988-09       Impact factor: 5.788

3.  Callosal apraxia.

Authors:  N R Graff-Radford; K Welsh; J Godersky
Journal:  Neurology       Date:  1987-01       Impact factor: 9.910

4.  Carbamazepine metabolism in man. Induction and pharmacogenetic aspects.

Authors:  M Eichelbaum; T Tomson; G Tybring; L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

5.  Pharmacokinetics: time-dependent changes--autoinduction of carbamazepine epoxidation.

Authors:  L Bertilsson; T Tomson; G Tybring
Journal:  J Clin Pharmacol       Date:  1986 Jul-Aug       Impact factor: 3.126

6.  Potent therapeutic effect of carbamazepine-10,11-epoxide in trigeminal neuralgia.

Authors:  T Tomson; L Bertilsson
Journal:  Arch Neurol       Date:  1984-06

7.  Carbamazepine 10, 11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants.

Authors:  M J Brodie; G Forrest; W G Rapeport
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

8.  Carbamazepine and its -10,11-epoxide metabolite in plasma and CSF. Relationship to antidepressant response.

Authors:  R M Post; T W Uhde; J C Ballenger; D C Chatterji; R F Greene; W E Bunney
Journal:  Arch Gen Psychiatry       Date:  1983-06

Review 9.  Clinical pharmacokinetics of carbamazepine.

Authors:  R H Levy; B M Kerr
Journal:  J Clin Psychiatry       Date:  1988-04       Impact factor: 4.384

10.  Carbamazepine substitution in severe partial epilepsy: implication of autoinduction of metabolism.

Authors:  G J Macphee; M J Brodie
Journal:  Postgrad Med J       Date:  1985-09       Impact factor: 2.401

View more
  14 in total

Review 1.  Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation.

Authors:  P Glue; C R Banfield; J L Perhach; G G Mather; J K Racha; R H Levy
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

2.  Carbamazepine-induced acute generalized exanthematous pustulosis: a case report.

Authors:  Saadia Skalli; Pierre Barret; Céline Villier; Jean-François Bussières
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

3.  Utility of physiologically based absorption modeling in implementing Quality by Design in drug development.

Authors:  Xinyuan Zhang; Robert A Lionberger; Barbara M Davit; Lawrence X Yu
Journal:  AAPS J       Date:  2011-01-05       Impact factor: 4.009

4.  A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.

Authors:  A D Huitema; R A Mathôt; M M Tibben; S Rodenhuis; J H Beijnen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

5.  The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.

Authors:  A V Boddy; M Cole; A D Pearson; J R Idle
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  New insights into the pharmacokinetics and metabolism of (R,S)-ifosfamide in cancer patients using a population pharmacokinetic-metabolism model.

Authors:  M P Di Marco; I W Wainer; C L Granvil; G Batist; M P Ducharme
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

Review 7.  Herb-drug interactions: a literature review.

Authors:  Zeping Hu; Xiaoxia Yang; Paul Chi Lui Ho; Sui Yung Chan; Paul Wan Sia Heng; Eli Chan; Wei Duan; Hwee Ling Koh; Shufeng Zhou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Early stage autoinduction of carbamazepine metabolism in humans.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

9.  Lymphocyte microsomal epoxide hydrolase in patients on carbamazepine therapy.

Authors:  M Pirmohamed; R Allott; V J Green; N R Kitteringham; D Chadwick; B K Park
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

10.  Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine.

Authors:  Vincent L M Yip; Henry Pertinez; Xiaoli Meng; James L Maggs; Daniel F Carr; B Kevin Park; Anthony G Marson; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2020-12-14       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.